FORSYTH DOUGLAS — SEC insider filings
SEC reporting owner CIK 1240801. 12 insider filings on record with FilingPulse; latest filed 2026-09-18.
Transaction summary — filings shown
Covers all 12 filings on record, filed 2020-08-13 to 2026-09-18. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 3 legs across 2 filings — 77,500 shares, $1,323,945 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 9 legs across 1 filing — 20,000 shares, $493,271 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 15.
- Largest priced transaction: purchase of 59,812 shares @ $14.07 ($841,555) in Inhibrx Biosciences, Inc., filed 2024-08-26.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Inhibrx Biosciences, Inc. (INBX) | Director | 6 | 3 legs · 77,500 sh · $1,323,945 | — | 5 |
| AllianzGI Equity & Convertible Income Fund (NIE) | — | 1 | — | 9 legs · 20,000 sh · $493,271 | — |
| Inhibrx, Inc. (INBX) | Director | 5 | — | — | 10 |
Insider filings — FORSYTH DOUGLAS
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-18 | 4/A | Inhibrx Biosciences, Inc. (INBX) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-09-08 | 4 | Inhibrx Biosciences, Inc. (INBX) | Purchase (P): 2,500 @ $114.65 | EDGAR |
| 2026-06-04 | 4 | Inhibrx Biosciences, Inc. (INBX) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-05-29 | 4 | Inhibrx Biosciences, Inc. (INBX) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2024-08-26 | 4 | Inhibrx Biosciences, Inc. (INBX) | Purchase (P): 15,188 @ $12.89 · Purchase (P): 59,812 @ $14.07 | EDGAR |
| 2024-05-30 | 4 | Inhibrx Biosciences, Inc. (INXB) | Grant/award (A): 149,564 · Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-05-30 | 4 | Inhibrx, Inc. (INBX) | Disposition to issuer (D): 598,257 @ $30 · Disposition to issuer (D): 17,259 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) | EDGAR |
| 2023-05-30 | 4 | Inhibrx, Inc. (INBX) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2022-05-26 | 4 | Inhibrx, Inc. (INBX) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2021-06-08 | 4 | Inhibrx, Inc. (INBX) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2020-08-21 | 4 | Inhibrx, Inc. (INBX) | Conversion (C): 82,422 @ $0 · Conversion (C): 143,266 (derivative) @ $0 | EDGAR |
| 2020-08-13 | 4 | AllianzGI Equity & Convertible Income Fund (NIE) | Sale (S): 10,000 @ $24.68 · Sale (S): 100 @ $24.69 · Sale (S): 100 @ $24.67 · Sale (S): 800 @ $24.66 · Sale (S): 1,791 @ $24.70 · Sale (S): 709 @ $24.66 · +3 more | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-08-10 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1240801 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs